| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Notes: |
Hameatology/Oncology related Prescribing Guidance
Please see our Prescribing Guidelines page for all prescribing guidance relating to this chapter.
Haematology/Oncology related Shared Care Agreements
Please see our Shared Care Agreements page for all shared care agreements (SCAs) relating to this chapter.
|
|
|
| Details... |
| 08.01 |
Cytotoxic drugs |
|
|
| 08.01 |
Drugs for cytotoxic-induced side-effects |
|
|
Calcium Folinate
(Injection)
|
Formulary
 
|
- Folinic acid (as Calcium folinate) 7.5mg per 1ml
- Chemotherapy induced mucositis and myelosuppression
|
|
|
Mesna
(Injection)
|
Formulary
|
- 1m/10ml solution for injection
- Chemotherapy induced neutropenic infection and nephrotoxicity
|
|
|
Mesna
(Tablets)
|
Formulary
|
- 400mg or 600mg tablets
- Chemotherapy induced neutropenic infection and nephrotoxicity
|
|
|
| 08.01.01 |
Alkylating drugs |
|
|
Bendamustine
(Injection)
|
Formulary
|
|
 NICE TA216: Bendamustine for CLL
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
|
Busulfan
(Tablets)
|
Formulary
|
|
|
|
Busulfan
(Injection)
|
Formulary
|
|
|
|
Cyclophosphamide
(Tablets)
|
Formulary
|
|
|
|
Cyclophosphamide
(Injection)
|
Formulary
|
- 500mg,1g and 2g injection
|
|
|
Ifosfamide
(Injection)
|
Formulary
|
|
|
|
Lomustine
(Capsules)
|
Formulary
|
|
|
|
Melphalan
(Tablets)
|
Formulary
|
|
|
|
Melphalan
(Injection)
|
Formulary
|
- 50mg powder and solvent for injection
|
|
|
Chlormethine Hydrochloride (Mustine)
(Injection )
|
 Unlicensed
|
- 10mg powder for reconstitution
|
|
|
| 08.01.02 |
Anthracyclines and other cytotoxic antibiotics |
|
|
Bleomycin
(Injection)
|
Formulary
|
- 15,000 unit powder for injection
|
|
|
Dactinomycin
(Injection)
|
Formulary
|
- 500microgram powder for reconstitution
|
|
|
Daunorubicin
(Injection)
|
Formulary
|
|
|
|
Doxorubicin
(Injection)
|
Formulary
|
- 10mg/5ml, 50mg/25ml, 100mg/50ml and 200mg/100ml injection
|
|
|
Doxorubicin
(Caelyx®)
(Liposomal injection)
|
Formulary
|
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
Epirubicin
(Injection)
|
Formulary
|
- 10mg/5ml and 50mg/25ml injection
- 100mg/50ml, 200mg/100ml infusion
|
|
|
Idarubicin
(Injection and capsules)
|
Formulary
|
- 5mg, 10mg and 25mg capsules
- 5mg and 10mg injection
|
|
|
Mitomycin
(Injection)
|
Formulary
|
|
|
|
Mitoxantrone
(Injection)
|
Formulary
|
|
|
|
Pixantrone
(Injection)
|
Formulary
|
|
NICE TA306: Pixantrone monotherapy
|
| 08.01.03 |
Antimetabolites |
|
|
Azacitidine
(Injection)
|
Formulary
|
|
NICE TA218: azacitidine for myelodysplastic syndromes
|
Capecitabine
(Tablets)
|
Formulary
|
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
NICE TA191: Gastric cancer (advanced) - capecitabine
|
Cladribine
(Injection)
|
Formulary
|
- 10mg tablet
- 10mg/10ml solution for infusion
- 10mg/5ml solution for injection
- For specialist use only in accordance with guidance from cancer network or NICE
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis
|
Cytarabine
(Injection)
|
Formulary
|
- 100mg/5ml, 500mg/25ml, 1g/10ml, 2g/20ml and 500g/5ml injection
|
|
|
Fludarabine Phosphate
(Injection)
|
Formulary
|
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine
NICE TA29: Leukaemia (lymphocytic) - fludarabine
|
Fludarabine Phosphate
(Tablets)
|
Formulary
|
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine
|
Fluorouracil
(Injection)
|
Formulary
|
- 250mg/10ml, 500ml/20ml, 500mg/10ml and 1g/20ml injection
- 2.5mg/100ml, 2.5mg/50ml and 5mg/100ml infusion
- For topical cream see chapter 13.8.1
|
|
|
Gemcitabine
(Injection)
|
Formulary
|
- Various strengths of infusion
|
NICE TA116: Breast cancer - gemcitabine
NICE TA25: Pancreatic cancer - gemcitabine
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
Mercaptopurine
(Tablets)
|
Formulary
|
- 50mg tablets
- Note: Only the 50mg strength tablets are included on the formulary for gastro indications in adults. 10mg strength tablets are unlicensed specials. Alternate dosing using 50mg/100mg should be considered where daily doses between 50 and 100mgs are required for adults.
- For use in children see paediatric chapter
- For use in Crohn's disease, see chapter 1
|
|
|
Methotrexate
(Tablets)
|
Formulary
|
|
|
|
Pemetrexed
(Injection)
|
Formulary
|
|
NICE TA135: Mesothelioma - pemetrexed disodium
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
|
Clofarabine
(Injection)
|
Unlicensed
|
- 20mg/20ml infusion
- ONLY Approved for use in acute myeloblastic leukaemia in accordance with the criteria set out by the NHS England Cancer Drugs Fund
|
|
|
| 08.01.04 |
Vinca alkaloids and etoposide |
|
|
Etoposide
(Injection)
|
Formulary
|
- 100mg/5ml, 200mg/10ml and 500mg/25ml infusion
|
|
|
Etoposide
(Capsules)
|
Formulary
|
|
|
|
Vinblastine Sulphate
(Injection)
|
Formulary
|
- 1mg/10ml solution for injection
|
|
|
Vincristine Sulphate
(Injection )
|
Formulary
|
- 1mg/1ml, 2mg/2ml and 5mg/5ml injection
|
|
|
Vindesine Sulphate
(Injection)
|
Formulary
|
|
|
|
Vinorelbine
(Capsules)
|
Formulary
|
- 20mg, 30mg and 80mg capsules
|
|
|
Vinorelbine
(Injection)
|
Formulary
|
- 10mg/1ml and 50mg/5ml infusion
|
|
|
| 08.01.05 |
Other antineoplastic drugs |
|
|
Abemaciclib
(Tablets)
|
Formulary
|
- 50mg, 100mg, 150mg film coated tablets
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
|
Atezolizumab
(Injection)
|
Formulary
|
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA520 : Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
|
Avelumab
(injection)
|
Formulary
|
- 200mg/10ml concentrate for solution for infusion vials
- For use in combination with axitinib in line with NICE TA645 [Not at SFT]
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma
|
Axitinib
(Tablets)
|
Formulary
|
- 1mg, 3mg, 5mg and 7mg tablets
|
NICE TA333: Axitinib for advanced renal cell carcinoma
NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma
|
Bosutinib
(Tablets)
|
Formulary
|
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
|
Brigatinib
(Tablets)
|
Formulary
|
|
NICE TA571 :Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
|
Cabozantinib
(Tablets)
|
Formulary
|
- 20mg, 40mg and 60mg tablets
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
|
Carfilzomib
(Injection)
|
Formulary
|
- 10mg, 30mg and 60mg infusion
|
NICE TA457 : Carfilzomib for previously treated multiple myeloma
NICE TA657: Carfilzomib for previously treated multiple myeloma
MHRA November 2019 - Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus
MHRA August 2019 - Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events
|
Ceritinib
(Capsules)
|
Formulary
|
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
|
Dabrafenib
(Capsules)
|
Formulary
|
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanom
|
Daratumumab
(Injection)
|
Formulary
|
|
 MHRA Drug Safety Update (Aug 2019): Daratumumab (Darzalex¥): risk of reactivation of hepatitis B virus
|
Defibrotide
(Injection)
|
 Restricted
|
- 200mg (80 mg/mL concentrate for solution for infusion)
- For the treatment of veno-occlusive disease in accordance with treatment of possible hepatic veno-occlusive disease as noted in link below
- Formulary at RUH for this indication
|
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Durvalumab
(Injection)
|
Formulary
|
- 50 mg/mL concentrate for solution for infusion
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
|
Eribulin
(Injection)
|
Formulary
|
- 0.88mg/2ml solution for injection
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
|
Ibrutinib
(Capsules)
|
Formulary
|
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
|
Idelalisib
(Tablets)
|
Formulary
|
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
|
Inotuzumab Ozogamicin
(Injection)
|
Formulary
|
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Isatuximab
(injection)
|
Formulary
|
- 20mg/ml concentrate for solution for infusion vials
- For use in combination with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in line with TA658.
axitinib in line with NICE TA645
|
NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
|
Ixazomib
(Capsules)
|
Formulary
|
- 2.3mg, 3mg and 4mg capsules
- To treat relapsed/defractory myeloma in combination with Lenalidomaide and Dexamethasone
- To treat multple myeloma via the Cancer Drugs Fund
|
|
|
Lenvatinib
(Capsules)
|
Formulary
|
- 4mg and 10mg capsules
- Different brand depending upon indication
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
|
Lenvatinib with Everolimus
(Capsules)
|
Formulary
|
- 4mg and 10mg capsules
- Different brand depending upon indication
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Midostaurin
(Capsules)
|
Formulary
|
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia
|
Nintedanib
(Capsules)
|
Formulary
|
|
NICE TA347 For treating locally advanced, metastatic or locally recurrant non-small-cell lung cancer
|
Palbociclib
(Capsules)
|
Formulary
|
- 75mg, 100mg and 125mg capsules
|
NICE TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic brest cancer
NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
|
Panitumumab
(Injection)
|
Formulary
|
- 100mg/5ml and 400mg/20ml infusion
|
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
|
Pembrolizumab
(Injection)
|
Formulary
|
- 100mg/4ml concentration for solution for infusion
- 50mg powder for concentration for solution for infusion
- Also available from NHS England Cancer Drugs Fund
- NICE does not recommend pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650).
|
NICE TA357: Pembrolizumab for melanoma after ipilimumab
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (not recommended)
NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
|
Polatuzumab vedotin
(Injection)
|
Formulary
|
- 140mg powder for concentrate for solution for infusion vials
- For use in combination with rituximab and bendamustine in line with NICE TA649
|
NICE TA649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
|
Ponatinib
(Tablets)
|
Formulary
|
- 15mg, 30mg and 45mg tablets
|
NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
|
Ruxolitinib
(Tablets)
|
Formulary
|
- 5mg, 10mg, 15mg and 20mg tablets
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
|
Trametinib
(Tablets)
|
Formulary
|
|
MHRA: Trametinib (Mekinist¥): risk of gastrointestinal perforation and colitis
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
Trifluridine-tipiracil
(Tablets )
|
Formulary
|
- 15mg/6.14mg and 20mg/8.19mg tablets
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
|
Venetoclax
(Tablets)
|
Formulary
|
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
|
| 08.01.05 |
Amsacrine |
|
|
Amsacrine
(Injection)
|
Formulary
|
- 75mg/1.5ml solution for infusion ampoules and diluent
|
|
|
| 08.01.05 |
Arsenic trioxide |
|
|
Arsenic Trioxide
(Injection)
|
Formulary
|
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
|
| 08.01.05 |
Bortezomib |
|
|
Bortezomib
(Injection)
|
Formulary
|
|
NICE TA129: Multiple myeloma - bortezomib
NICE TA228: 1st line treatment of multiple myeloma
NICE TA311: Bortezomib for induction therapy in multiple myeloma
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
|
| 08.01.05 |
Brentuximab vedotin |
|
|
Brentuximab
(Injection)
|
Formulary
|
|
NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
NICE TA641 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
|
| 08.01.05 |
Cetuximab |
|
|
Cetuximab
(Injection)
|
Formulary
|
|
NICE TA145: Head and neck cancer - cetuximab
NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
Dacarbazine
(Injection)
|
Formulary
|
- 500mg and 1g infusion
- 100mg and 200mg injection
|
|
|
Temozolomide
(Capsules)
|
Formulary
|
- 5mg, 20mg, 100mg, 140mg, 180mg and 250mg capsules
|
NICE TA121: Glioma (newly diagnosed and high grade)
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
|
| 08.01.05 |
Erlotinib |
|
|
Erlotinib
(Tablets)
|
Formulary
|
- 25mg, 100mg and 150mg tablets
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
| 08.01.05 |
Hydroxycarbamide |
|
|
Hydroxycarbamide
(Capsules)
|
Formulary
|
- RUH
 SFT and GWR- 500mg capsules
|
3Ts Hydroxycarbamide Shared Care Document
SFT Hydroxycarbamide Shared Care Document
|
| 08.01.05 |
Ipilimumab |
|
|
Ipilimumab
(Injection)
|
Formulary
|
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
MHRA Drug Safety Update (Jan 2019):Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
|
| 08.01.05 |
Pentostatin |
|
|
Pentostatin
(Injection)
|
Formulary
|
|
|
|
| 08.01.05 |
Platinum compounds |
|
|
Carboplatin
(Injection)
|
Formulary
|
- 150mg/15ml, 450mg/45ml, 50mg/5ml and 600mg/60ml infusion
|
|
|
Cisplatin
(Injection)
|
Formulary
|
- 10mg/10ml, 50mg/50ml and 100mg/100ml infusion
|
|
|
Oxaliplatin
(Injection)
|
Formulary
|
- 50mg/10ml, 100mg/20ml and 200mg/40ml infusion
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
|
| 08.01.05 |
Procarbazine |
|
|
Procarbazine
(Capsules)
|
Formulary
|
|
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib
(Tablets)
|
Formulary
|
- 20mg, 30mg, 40mg and 50mg tablets
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Cabozantinib
(Oral)
|
Formulary
|
|
NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA516: Cabozantinib for treating medullary thyroid cancer
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
|
Crizotinib
(Tablets)
|
Formulary
|
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
|
Dasatinib
(Tablets)
|
Formulary
|
- 20mg, 50mg, 80mg, 100mg and 140mg tablets
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Entrecitinib
(Capsules)
|
Formulary
|
- 100mg, 200mg capsules
- Use in line with NICE TA643 and 644
|
NICE TA 644 Entrectinib for treating NTRK fusion-positive solid tumours
NICE TA643 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
|
Everolimus
(Afinitor®)
(Tablets)
|
Formulary
|
- 2.5mg, 5mg and 10mg tablets
- Ensure correct brand is prescribed.
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Everolimus
(Votubia®)
(Tablets)
|
Formulary
|
- Only at RUH
- 2.5mg, 5mg and 10mg tablets
- Ensure correct brand is supplied
- To be prescribed by specialist centres in accordance with NHSE commissioning policies
|
Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)
Clinical Commissioning Policy: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)
|
Gefitinib
(Tablets)
|
Formulary
|
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
Gilteritinib
(Tablets)
|
Formulary
|
- 40mg tablets
- Use in line with NICE TA642
|
NICE TA642 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
|
Imatinib
(Gilvec®)
(Tablets)
|
Formulary
|
- 100mg and 400mg tablets
- Ensure correct brand supplied
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
|
Imatinib (Generic)
(Tablets)
|
Formulary
|
- 100mg and 400mg tablets
- Also for treatment of Philadelphia Positive Guidelines ALL as per BCSH Guidelines
|
NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Nilotinib
(Capsules)
|
Formulary
|
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Pazopanib
(Tablets)
|
Formulary
|
|
NICE TA215: Pazopanib in renal cell cancer
|
Regorafenib
(Tablets)
|
Formulary
|
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
|
Sorafenib
(Tablets)
|
Formulary
|
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
|
Sunitinib
(Capsules)
|
Formulary
|
- 12.5mg, 25mg and 50mg capsules
|
NICE TA169: Renal cell carcinoma - sunitinib
NICE TA179: Gastrointestinal stromal tumours - sunitinib
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Tivozanib
(Capsules)
|
Formulary
|
- 890microgram and 1340microgram capsules
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tivozanib for treating advanced renal cell carcinoma
|
Vemurafenib
(Tablets)
|
Formulary
|
|
NICE TA269: Vemurafenib for treating malignant melanoma
|
| 08.01.05 |
Taxanes |
|
|
Cabazitaxel
(Injection)
|
Formulary
|
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
|
Docetaxel
(Injection)
|
Formulary
|
- Various concentrations of infusion
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
NICE TA109: Breast cancer (early) - docetaxel
|
Paclitaxel
(Injection)
|
Formulary
|
- Various strengths of concentration
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
|
Paclitaxel
(Abraxane®)
(Injection)
|
Formulary
|
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
Irinotecan hydrochloride
(Injection )
|
Formulary
|
- 500mg/25ml, 300mg/15ml, 100mg/5ml and 40mg/2ml infusion
|
MHRA Drug Safety Update (Mar 2019):Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events
|
Topotecan
(Injection)
|
Formulary
|
|
NICE TA183: Cervical cancer (recurrent) - topotecan
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
Topotecan
(Capsules)
|
Formulary
|
- 250microgram and 1mg capsules
|
NICE TA184: Lung cancer (small-cell) - topotecan
|
| 08.01.05 |
Trabectedin |
|
|
Trabectedin
(Injection)
|
Formulary
|
- 250microgram and 1mg infusion
|
NICE TA185: Soft tissue sarcoma - trabectedin
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
| 08.01.05 |
Trastuzumab |
|
|
Pertuzumab
(Injection)
|
Formulary
|
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
|
Trastuzumab
(Injection)
|
Formulary
|
- 600mg/5ml injection Herceptin®
- 150mg and 420mg infusion Ontruzant®
- Prescribe by brand. Biosimilar Ontruzant first line option
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
NICE TA34: Breast cancer - trastuzumab
|
Trastuzumab emtansine
(Kadcyla®)
(Injection)
|
Formulary
|
|
NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan
|
| 08.01.05 |
Tretinoin |
|
|
Tretinoin
(Capsules)
|
Formulary
|
|
|
|
| 08.01.05 |
Vismodegib |
|
|
| .... |
| Non Formulary Items |
Anamorelin
|
Non Formulary
|
|
|
|
Anamorelin
|
Non Formulary
|
|
|
|
Carmustine
(Implant)
|
Non Formulary
|
- 7.7mg implant
- Non Formulary except when used within a specialist centre as per NICE TA
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
|
Chlorambucil
(Leukeran®)
(Tablets)
|
Non Formulary
|
|
|
|
Dexrazoxane
|
Non Formulary
|
For anthracycline extravasation |
|
|
Disodium Levofolinate
(Lvofolinic acid )
|
Non Formulary
|
|
|
|
Olaratumab
(Lartruvo®)
|
Non Formulary
|
Discontinued |
|
|
Oxaliplatin
|
Non Formulary
|
|
|
|
Raltitrexed
|
Non Formulary
|
|
|
|
Rociletinib
|
Non Formulary
|
|
|
|
Sonidegib
(Odomzo®)
|
Non Formulary
|
|
|
|
Thiotepa
|
Non Formulary
|
|
|
|
Tioguanine
|
Non Formulary
|
|
|
|
Treosulfan
|
Non Formulary
|
Commissioned as per national guidance in combination with Fludarabine in line with NICE TA640. Condition not treated at GWH/RUH/SFT |
NICE TA 640 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
|
Vismodegib
(Capsules)
|
Non Formulary
|
- 150mg capsule
- Not recommended by NICE
|
NICE TA489: Vismodegib for treating basal cell carcinoma
|
Vosaroxin
(Qinprezo)
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
High Cost Drug Approval System |
|
Traffic Light Status Information
|
|
|
